These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15464942)

  • 21. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
    Gurm HS; Smith DE; Chetcuti SJ; Share D; Khanal S; Riba A; Carter AJ; Lalonde T; Kline-Rogers E; O'Donnell M; O'Neill W; Safian R; Moscucci M;
    J Interv Cardiol; 2007 Jun; 20(3):197-203. PubMed ID: 17524111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention.
    Delhaye C; Maluenda G; Wakabayashi K; Ben-Dor I; Collins SD; Syed AI; Gonzalez MA; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    Am J Cardiol; 2010 Feb; 105(3):297-301. PubMed ID: 20102938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
    Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Popma JJ; Berger P; Ohman EM; Harrington RA; Grines C; Weitz JI
    Chest; 2004 Sep; 126(3 Suppl):576S-599S. PubMed ID: 15383485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction.
    Chu WW; Kuchulakanti PK; Wang B; Torguson R; Clavijo LC; Pichard AD; Suddath WO; Satler LF; Kent KM; Waksman R
    Cardiovasc Revasc Med; 2006; 7(3):132-5. PubMed ID: 16945819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction.
    Dauerman HL; Frederick PD; Miller D; French WJ;
    Coron Artery Dis; 2007 Mar; 18(2):141-8. PubMed ID: 17301606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Stella JF; Stella RE; Iaffaldano RA; Stella DJ; Erickson KW; Bliley RC
    J Invasive Cardiol; 2004 Sep; 16(9):451-4. PubMed ID: 15353822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.
    Bittl JA; Strony J; Brinker JA; Ahmed WH; Meckel CR; Chaitman BR; Maraganore J; Deutsch E; Adelman B
    N Engl J Med; 1995 Sep; 333(12):764-9. PubMed ID: 7643883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
    Gurm HS; Sarembock IJ; Kereiakes DJ; Young JJ; Harrington RA; Kleiman N; Feit F; Wolski K; Bittl JA; Wilcox R; Topol EJ; Lincoff AM
    J Am Coll Cardiol; 2005 Jun; 45(12):1932-8. PubMed ID: 15963389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of bivalirudin to prevent subacute thrombosis during drug-eluting stent implantation.
    Medina RP; Foto D
    J Invasive Cardiol; 2004 May; 16(5):236-9. PubMed ID: 15152125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bivalirudin in PCI: an overview of the REPLACE-2 trial.
    Maroo A; Lincoff AM
    Semin Thromb Hemost; 2004 Jun; 30(3):329-36. PubMed ID: 15282655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention.
    Marso SP; Amin AP; House JA; Kennedy KF; Spertus JA; Rao SV; Cohen DJ; Messenger JC; Rumsfeld JS;
    JAMA; 2010 Jun; 303(21):2156-64. PubMed ID: 20516416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of prolonged bivalirudin infusions following percutaneous coronary intervention.
    Moser LR; Nemerovski CW; Good KL
    Cardiovasc Drugs Ther; 2011 Jun; 25(3):267-76. PubMed ID: 21479645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brachytherapy and bivalirudin evaluation study.
    Kuchulakanti P; Wolfram R; Torguson R; Rha SW; Cheneau E; Pinnow EE; Canos D; Satler LF; Pichard AD; Kent KM; Waksman R
    Am Heart J; 2005 Oct; 150(4):832-7. PubMed ID: 16209990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic implications of bivalirudin in the cardiac catheterization laboratory.
    Bakhai A; Cohen DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 3():S35-42. PubMed ID: 17224883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Brodie BR
    Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
    Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.